Set Your Location to See Relevant Information

Setting your location helps us to show you nearby providers and locations based on your healthcare needs.

We are now offering COVID-19 vaccine appointment scheduling at our Walk-In Center at 292 Long Ridge Road. Please remember, masks are required in all Stamford Health facilities and you may be asked to provide proof of vaccination.

ULTRA-V: Phase 2/3 Randomized Study to Assess the Efficacy and Safety of Ublituximab in Combination with Umbralisib and Venetoclax (U2-V) Compared to Ublituximab and Umbralisib (U2) in Subjects with Chronic Lymphocytic Leukemia (CLL) (TG Therapeutics U2-VEN-207)

Study Details

This is an open-label, multicenter, Phase 2/3 study to evaluate the efficacy and safety of the combination of ublituximab + umbralisib + venetoclax (U2-V) compared to the combination of ublituximab + umbralisib (U2) in patients with either treatment naïve or previously treated CLL

Learn More NCT number

Principal Investigators

  • Anthony Gulati, MD
TG Therapeutics, Inc.
Ed Hatton, RN at 203-358-8879


  • Bennett Cancer Center
    One Hospital Plaza
    Stamford, CT 06902
    Main: 203-276-2695

Our website uses cookies

This website uses cookies to give you the very best experience. Your continued use of this site is considered permission by you to use cookies in this manner. Please review our Privacy Policy and Terms of Use for more information about the data we collect and the types of cookies we use. Please note, if you link off our website to a 3rd party site of any kind, that website has its own terms and conditions.